BCL2 and diffuse large B-cell lymphoma: NF-κB profiling (Fig. 2B) revealed a vulnerability to NIK inhibition (Fig. 2D, E), indicating the potential for combined NF-κB and BCL2 “fingerprinting” to inform the rational assignment of therapeutic agents targeting multiple pathways in DLBCL.